Joshua Zeidner, MD, associate professor of medicine and chief of leukemia research at UNC Lineberger, is the corresponding author of a newly published study on a promising treatment approach for acute myeloid leukemia (AML). The early-phase clinical trial, conducted at 12 centers nationwide, tested whether adding the oral menin inhibitor revumenib to the standard AML regimen of azacitidine and venetoclax is safe and effective for newly diagnosed older adults with specific gene mutations.
Results showed an 88.4% overall response rate and a 67.4% complete remission rate, with 84% of responders achieving remission within the first 28-day cycle. These rates exceeded those typically seen with the standard treatment alone. The trial’s success has led to the launch of a randomized phase 3 trial, where Dr. Zeidner will serve as the lead U.S. investigator and UNC Lineberger will be the lead U.S. site.
For more information about the study visit UNC Linebergers’ site.